Age: 57.0
Sex: F
Vaccine: MENB, MNQ
Symptoms: Extra dose administered, Product administered to patient of inappropriate age, Splenectomy
Clinical narrative: a patient had their spleen removed; Inappropriate age at vaccine administration Menevo; Extra dose; now getting vaccinations again. The patient completed the Bexsero series when they were younger they are now over 40 years of age; This serious case was reported by a pharmacist via call center representative and described the occurrence of splenectomy in a 57-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA982A, expiry date 31-OCT-2024) for prophylaxis.   Co-suspect products included Men B NVS (Bexsero) (batch number 95NJ4, expiry date 30-SEP-2026) for prophylaxis and Men B NVS (Bexsero) for prophylaxis.   On 26-JAN-2024, the patient received Menveo. On 21-JAN-2024, the patient received the 3rd dose of Bexsero. On an unknown date, the patient received the 2nd dose of Bexsero. On 21-JAN-2024, not applicable after receiving Menveo and Bexsero and an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: Extra dose) and inappropriate age at vaccine administration (Verbatim: now getting vaccinations again. The patient completed the Bexsero series when they were younger they are now over 40 years of age). On 26-JAN-2024, the patient experienced inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration Menevo). On an unknown date, the patient experienced splenectomy (Verbatim: a patient had their spleen removed) (serious criteria clinically significant/intervention required). The outcome of the splenectomy, extra dose administered, inappropriate age at vaccine administration and inappropriate age at vaccine administration were unknown.   It was unknown if the reporter considered the splenectomy to be related to Bexsero and Bexsero Pre-Filled Syringe Device.     It was unknown if the company considered the splenectomy to be related to Bexsero and Bexsero Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 13-FEB-2024 The pharmacist called to inquire the way to proceed with Bexsero series. Registered pharmacist (RPH) explained a patient had their spleen removed and nowgetting vaccinations again. The patient completed the Bexsero series when they were younger they were now over 40 years of age. The reporter asked if that patient need three doses or boosters.  The health care professional (HCP) mentioned that they already administered one dose of Bexsero. The reporter inquiring available about the recommendation for the administration of Menveo and timing after the administration of Menveo and Bexsero.  The question was verified and cleared up, to which he pharmacist confirmed that they wished to know the spacing.  Information about the patient, event and vaccine was provided.  The Vaccine Administration Facility was the same as Primary Reporter The patient received one dose of Bexsero recently after the complete vaccination series, which led to extra dose administered. The 57 years patient received Menveo and Bexsero, which led to inappropriate age at vaccine administered The reporter did not consent to follow-up